Lucas Moreno

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. doi request reprint Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience
    Lucas Moreno
    Children and Young People s Unit, The Royal Marsden NHS Foundation Trust The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Pediatr Blood Cancer 60:1135-40. 2013
  2. doi request reprint How can attrition rates be reduced in cancer drug discovery?
    Lucas Moreno
    Paediatric Drug Development, Children and Young People s Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton SM2 5PT, UK 44 0 208 661 3678 44 0 208 661 3617
    Expert Opin Drug Discov 8:363-8. 2013
  3. ncbi request reprint Preclinical drug development for childhood cancer
    Lucas Moreno
    The Royal Marsden NHS Foundation Trust, Children and Young People s Unit, Sutton, Surrey, UK
    Expert Opin Drug Discov 6:49-64. 2011

Detail Information

Publications3

  1. doi request reprint Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience
    Lucas Moreno
    Children and Young People s Unit, The Royal Marsden NHS Foundation Trust The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Pediatr Blood Cancer 60:1135-40. 2013
    ..The aim of this study was to identify the nature and severity of late complications of metastatic neuroblastoma survivors included in the ENSG5 clinical trial...
  2. doi request reprint How can attrition rates be reduced in cancer drug discovery?
    Lucas Moreno
    Paediatric Drug Development, Children and Young People s Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton SM2 5PT, UK 44 0 208 661 3678 44 0 208 661 3617
    Expert Opin Drug Discov 8:363-8. 2013
    ..Finally, there is a need for increased collaboration to combine the unique strengths between industry, academia and regulators to ensure that the needs of all stakeholders are met...
  3. ncbi request reprint Preclinical drug development for childhood cancer
    Lucas Moreno
    The Royal Marsden NHS Foundation Trust, Children and Young People s Unit, Sutton, Surrey, UK
    Expert Opin Drug Discov 6:49-64. 2011
    ..More effective drugs are needed to treat poor prognosis paediatric malignancies. Development of anticancer agents for childhood cancers faces several unique challenges compared with their adult counterparts...